Aims: Coupled responses of mutated K-ras and oxidative stress are often an important etiological factor in non–small-cell lung cancer (NSCLC). However, relatively few studies have examined the control mechanism of oxidative stress in oncogenic K-ras-driven NSCLC progression. Here, we studied whether the redox signaling pathway governed by peroxiredoxin I (Prx I) is involved in K-rasG12D-mediated lung adenocarcinogenesis. Results: Using human-lung adenocarcinoma tissues and lung-specific K-rasG12D-transgenic mice, we found that Prx I was significantly up-regulated in the tumor regions via activation of nuclear erythroid 2-related factor 2 (Nrf2) transcription. Interestingly, the increased reactive oxygen species (ROS) by null mutation of Prx I greatly promoted K-rasG12D-driven lung tumorigenesis in number and size, which appeared to require the activation of the ROS-dependent extracellular signal-regulated kinase (ERK)/cyclin D1 pathway. Innovation: Taken together, these results suggest that Prx I functions as an Nrf2-dependently inducible tumor suppressant in K-ras-driven lung adenocarcinogenesis by opposing ROS/ERK/cyclin D1 pathway activation. Conclusion: These findings provide a better understanding of oxidative stress-mediated lung tumorigenesis. Antioxid. Redox Signal. 19, 482–496.
AlexandrovaAY, KopninPB, VasilievJM, KopninBP. ROS up-regulation mediates Ras-induced changes of cell morphology and motility. Exp Cell Res, 312:2066–2073. 2006.
3.
ArberN, SutterT, MiyakeM, KahnSM, VenkatrajVS, SobrinoA, WarburtonD, HoltPR, WeinsteinIB. Increased expression of cyclin D1 and the Rb tumor suppressor gene in c-K-ras transformed rat enterocytes. Oncogene, 12:1903–1908. 1996.
4.
AvilaPC, KropotovAV, KrutilinaR, KrasnodembskayA, TomilinNV, SerikovVB. Peroxiredoxin V contributes to antioxidant defense of lung epithelial cells. Lung, 186:103–114. 2008.
5.
BaeSH, SungSH, ChoEJ, LeeSK, LeeHE, WooHA, YuDY, KilIS, RheeSG. Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol-induced oxidative injury in mouse liver. Hepatology, 53:945–953. 2011.
6.
ButterfieldLH, MerinoA, GolubSH, ShauH. From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. Antioxid Redox Signal, 1:385–402. 1999.
ChangF, SteelmanLS, SheltonJG, LeeJT, NavolanicPM, BlalockWL, FranklinR, McCubreyJA. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review)Int J Oncol, 22:469–480. 2003.
9.
ChangJW, JeonHB, LeeJH, YooJS, ChunJS, KimJH, YooYJ. Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun, 289:507–512. 2001.
10.
ChenMF, KengPC, ShauH, WuCT, HuYC, LiaoSK, ChenWC. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys, 64:581–591. 2006.
11.
ChoiMH, LeeIK, KimGW, KimBU, HanYH, YuDY, ParkHS, KimKY, LeeJS, ChoiC, BaeYS, LeeBI, RheeSG, KangSW. Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature, 435:347–353. 2005.
12.
ColemanML, MarshallCJ, OlsonMF. Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J, 22:2036–2046. 2003.
13.
CollinsLG, HainesC, PerkelR, EnckRE. Lung cancer: diagnosis and management. Am Fam Physician, 75:56–63. 2007.
EglerRA, FernandesE, RothermundK, SereikaS, de Souza-PintoN, JarugaP, DizdarogluM, ProchownikEV. Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene, 24:8038–8050. 2005.
16.
FanJ, BertinoJR. K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene, 14:2595–2607. 1997.
17.
FujiiJ, IkedaY. Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep, 7:123–130. 2002.
18.
GravesJA, MetukuriM, ScottD, RothermundK, ProchownikEV. Regulation of reactive oxygen species homeostasis by peroxiredoxins and c-Myc. J Biol Chem, 284:6520–6529. 2009.
19.
HalilovicE, SheQB, YeQ, PagliariniR, SellersWR, SolitDB, RosenN. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res, 70:6804–6814. 2010.
20.
HenebergP. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr Med Chem, 16:706–733. 2009.
JemalA, SiegelR, XuJ, WardE. Cancer statistics, 2010. CA Cancer J Clin, 60:277–300. 2010.
25.
JoshiG, AluiseCD, ColeMP, SultanaR, PierceWM, VoreM, St ClairDK, ButterfieldDA. Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain. Neuroscience, 166:796–807. 2010.
KimHJ, ChaeHZ, KimYJ, KimYH, HwangsTS, ParkEM, ParkYM. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol, 19:285–298. 2003.
28.
KimJH, BognerPN, BaekSH, RamnathN, LiangP, KimHR, AndrewsC, ParkYM. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res, 14:2326–2333. 2008.
29.
KimYJ, AhnJY, LiangP, IpC, ZhangY, ParkYM. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res, 67:546–554. 2007.
30.
KimYJ, LeeWS, IpC, ChaeHZ, ParkEM, ParkYM. Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. Cancer Res, 66:7136–7142. 2006.
31.
KimYS, LeeHL, LeeKB, ParkJH, ChungWY, LeeKS, SheenSS, ParkKJ, HwangSC. Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer. Korean J Intern Med, 26:304–313. 2011.
32.
KleinEA, AssoianRK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci, 121:3853–3857. 2008.
33.
Le BelleJE, OrozcoNM, PaucarAA, SaxeJP, MottahedehJ, PyleAD, WuH, KornblumHI. Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner. Cell Stem Cell, 8:59–71. 2011.
34.
LeeS, ChoiH, KimE, KimH, ParkYH, YuDY, YoonSJ, KimJ, SheenY, ParkSN, YoonDY. Melphalan inhibits adenoma development through modulating the expression of K-ras-specific markers in K-ras Tg mice. Int J Oncol, 37:219–228. 2010.
LiL, ShojiW, OshimaH, ObinataM, FukumotoM, KannoN. Crucial role of peroxiredoxin III in placental antioxidant defense of mice. FEBS Lett, 582:2431–2434. 2008.
37.
LiuJJ, ChaoJR, JiangMC, NgSY, YenJJ, Yang-YenHF. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol Cell Biol, 15:3654–3663. 1995.
38.
MartindaleJL, HolbrookNJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol, 192:1–15. 2002.
39.
MitsudomiT, VialletJ, MulshineJL, LinnoilaRI, MinnaJD, GazdarAF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene, 6:1353–1362. 1991.
40.
NeumannCA, FangQ. Are peroxiredoxins tumor suppressors?Curr Opin Pharmacol, 7:375–380. 2007.
41.
NeumannCA, KrauseDS, CarmanCV, DasS, DubeyDP, AbrahamJL, BronsonRT, FujiwaraY, OrkinSH, Van EttenRA. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature, 424:561–565. 2003.
PapaiahgariS, ZhangQ, KleebergerSR, ChoHY, ReddySP. Hyperoxia stimulates an Nrf2-ARE transcriptional response via ROS-EGFR-PI3K-Akt/ERK MAP kinase signaling in pulmonary epithelial cells. Antioxid Redox Signal, 8:43–52. 2006.
44.
ParkJH, KimYS, LeeHL, ShimJY, LeeKS, OhYJ, ShinSS, ChoiYH, ParkKJ, ParkRW, HwangSC. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology, 11:269–275. 2006.
45.
ParkSY, YuX, IpC, MohlerJL, BognerPN, ParkYM. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Res, 67:9294–9303. 2007.
46.
PeeperDS, UptonTM, LadhaMH, NeumanE, ZalvideJ, BernardsR, DeCaprioJA, EwenME. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature, 386:177–181. 1997.
47.
RosselandCM, WierodL, FlinderLI, OksvoldMP, SkarpenE, HuitfeldtHS. Distinct functions of H-Ras and K-Ras in proliferation and survival of primary hepatocytes due to selective activation of ERK and PI3K. J Cell Physiol, 215:818–826. 2008.
48.
SchumackerPT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell, 10:175–176. 2006.
49.
ShiX, ZhangY, ZhengJ, PanJ. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal, 16:1215–1228. 2012.
50.
ShinoharaM, ShangWH, KuboderaM, HaradaS, MitsushitaJ, KatoM, MiyazakiH, SumimotoH, KamataT. Nox1 redox signaling mediates oncogenic Ras-induced disruption of stress fibers and focal adhesions by down-regulating Rho. J Biol Chem, 282:17640–17648. 2007.
51.
SlebosRJ, KibbelaarRE, DalesioO, KooistraA, StamJ, MeijerCJ, WagenaarSS, VanderschuerenRG, van ZandwijkN, MooiWJet al.K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med, 323:561–565. 1990.
52.
StresingV, BaltziskuetaE, RubioN, BlancoJ, ArribaM, VallsJ, JanierM, ClezardinP, Sanz-PamplonaR, NievaC, MarroM, DmitriP, SierraA. Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. Oncogene, 32:724–735. 2013.
53.
SunHN, KimSU, HuangSM, KimJM, ParkYH, KimSH, YangHY, ChungKJ, LeeTH, ChoiHS, MinJS, ParkMK, KimSK, LeeSR, ChangKT, LeeSH, YuDY, LeeDS. Microglial peroxiredoxin V acts as an inducible anti-inflammatory antioxidant through cooperation with redox signaling cascades. J Neurochem, 114:39–50. 2010.
54.
VachtenheimJ. Occurrence of ras mutations in human lung cancer. Minireview. Neoplasma, 44:145–149. 1997.
55.
VaqueJP, NavascuesJ, ShiioY, LaihoM, AjenjoN, MauleonI, MatallanasD, CrespoP, LeonJ. Myc antagonizes Ras-mediated growth arrest in leukemia cells through the inhibition of the Ras-ERK-p21Cip1 pathway. J Biol Chem, 280:1112–1122. 2005.
56.
WangXQ, LiH, Van PuttenV, WinnRA, HeasleyLE, NemenoffRA. Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. Mol Biol Cell, 20:791–800. 2009.
57.
WeinbergF, HamanakaR, WheatonWW, WeinbergS, JosephJ, LopezM, KalyanaramanB, MutluGM, BudingerGR, ChandelNS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A, 107:8788–8793. 2010.
58.
XiaC, MengQ, LiuLZ, RojanasakulY, WangXR, JiangBH. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res, 67:10823–10830. 2007.
59.
ZhangB, SuY, AiG, WangY, WangT, WangF. Involvement of peroxiredoxin I in protecting cells from radiation-induced death. J Radiat Res (Tokyo), 46:305–312. 2005.
60.
ZhangB, WangY, SuY. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett, 286:154–160. 2009.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
